Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics
Pharmaceutics · 13.03.2026 · 18 (3) · 358
DOI: 10.3390/pharmaceutics18030358 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 13.03.2026. Verfasst von Amir Nasrolahi Shirazi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, 2575 Yorba Linda Blvd., Fullerton, CA 92831, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Marshall B. Ketchum University, College of Pharmacy, Fullerton, CA, Chapman University School of Pharmacy, Irvine, CA.
Abstract (Originalsprache)
Gadolinium nanoparticles (GdNPs) have gained increasing attention as multifunctional metal-based nanoplatforms that extend far beyond their traditional use as magnetic resonance imaging (MRI) contrast agents. Their specific magnetic properties, tunable physicochemical features, and tunable biocompatibilities with biocompatible coatings give them great potential as drug delivery and theranostic applications. They offer greater stability, lower systemic toxicity, and more surface modification options compared to molecular gadolinium chelates. The functionalized GdNPs not only show excellent properties as drug carriers for their specific indications but also serve as agents in various imaging modalities with superior therapeutic efficacy by means of radio sensitization and magnetically assisted delivery. Note too that GdNP-based formulations have demonstrated synergistic activity when administered with chemotherapeutic agents such as doxorubicin. GdNPs have demonstrated promising preclinical outcomes, and their clinical translation remains restricted due to a number of scale-up constraints, long-term safety challenges, pharmacokinetics, and regulatory problems. This review provides information on the use of GdNPs, their key physicochemical and magnetic properties, ligand engineering for targeted delivery, and biological mechanisms of their theranostic performance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, 2575 Yorba Linda Blvd., Fullerton, CA 92831, USA.
- Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, 9401 Jeronimo Rd., Irvine, CA 92618, USA.
ORCID-Profile: Rajesh Vadlapatla, Keykavous Parang
Förderung
- NCI NIH HHS
- Marshall B. Ketchum University, College of Pharmacy, Fullerton, CA
- Chapman University School of Pharmacy, Irvine, CA
- NIH
Zitieren
APA
Shirazi, A. N., Vadlapatla, R., Koomer, A., Zayed, H., Marabut, P., & Parang, K. (2026). Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics. Pharmaceutics, 18(3), 358. https://doi.org/10.3390/pharmaceutics18030358
Vancouver
Shirazi AN, Vadlapatla R, Koomer A, Zayed H, Marabut P, Parang K. Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics. Pharmaceutics. 2026;18(3):358. doi:10.3390/pharmaceutics18030358
BibTeX
@article{Shirazi2026,
author = {Shirazi, Amir Nasrolahi and Vadlapatla, Rajesh and Koomer, Ajoy and Zayed, Heyam and Marabut, Paris and Parang, Keykavous},
title = {Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {3},
pages = {358},
doi = {10.3390/pharmaceutics18030358}
}
EUVIMED